Bio Sig Technologies, Inc. BSGM
We take great care to ensure that the data presented and summarized in this overview for BioSig Technologies, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BSGM
View allLatest Institutional Activity in BSGM
Top Purchases
Top Sells
About BSGM
BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.
Insider Transactions at BSGM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 21
2025
|
Morgan Lee Lekstrom Director |
BUY
Open market or private purchase
|
Indirect |
7,000
+50.0%
|
$21,000
$3.58 P/Share
|
|
Nov 18
2025
|
Ferdinand Groenewald CFO |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+16.9%
|
-
|
|
Nov 18
2025
|
Donald Browne Director |
BUY
Grant, award, or other acquisition
|
Direct |
125,000
+35.38%
|
-
|
|
Aug 14
2025
|
Frank Giustra > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
128,205
+50.0%
|
$384,615
$3.9 P/Share
|
|
Jul 25
2025
|
Frank Giustra > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
50,000
+50.0%
|
$200,000
$4.68 P/Share
|
|
May 29
2025
|
Ferdinand Groenewald CFO |
BUY
Grant, award, or other acquisition
|
Direct |
175,000
+42.68%
|
-
|
|
May 29
2025
|
Anthony N. Amato Director |
BUY
Grant, award, or other acquisition
|
Direct |
900,000
+22.89%
|
-
|
|
Apr 24
2025
|
Steven Eric Abelman Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,345
+18.43%
|
-
|
|
Apr 24
2025
|
Christopher Allen Baer Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,345
+18.43%
|
-
|
|
Apr 24
2025
|
Donald Browne Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,345
+18.43%
|
-
|
|
Apr 24
2025
|
Frederick Hrkac Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,345
+3.67%
|
-
|
|
Apr 24
2025
|
Anthony N. Amato Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,345
+1.08%
|
-
|
|
Apr 24
2025
|
Ferdinand Groenewald CFO |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+36.84%
|
-
|
|
Sep 11
2024
|
Anthony N. Amato Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,550,000
+31.25%
|
-
|
|
Jul 26
2024
|
Christopher Allen Baer Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+27.27%
|
-
|
|
Jul 26
2024
|
Steven Eric Abelman Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+27.27%
|
-
|
|
Jul 26
2024
|
Frederick Hrkac Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+4.84%
|
-
|
|
Jul 26
2024
|
Donald Browne Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+27.27%
|
-
|
|
Jun 07
2024
|
Frederick Hrkac Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+8.2%
|
-
|
|
Mar 01
2024
|
Frederick Hrkac Director |
BUY
Grant, award, or other acquisition
|
Direct |
500,000
+49.53%
|
-
|
Last 12 Months Summary
| Open market or private purchase | 185K shares |
|---|---|
| Grant, award, or other acquisition | 1.41M shares |